DDAH1参与调控精氨酸代谢介导肿瘤发展的研究进展  

Progress of DDAH1 involvement in arginine metabolism in tumors

作　　者：梁飞腾 邓琼 王铸 梁辉 LIANG Feiteng;DENG Qiong;WANG Zhu;LIANG Hui(The First Clinical College of Guangdong Medical University,Zhanjiang 524000,China;Department of Urology,Longhua District People's Hospital,Shenzhen 518000,China)

机构地区：[1]广东医科大学第一临床医学院,湛江524000 [2]深圳市龙华区人民医院泌尿外科,深圳518000

出　　处：《生命的化学》2023年第5期728-734,共7页Chemistry of Life

基　　金：广东省医学科学技术研究基金项目(B2022065)。

摘　　要：代谢重编程是恶性肿瘤的标志之一。调控肿瘤的代谢重编程过程可以用来诊断、监测和治疗癌症。精氨酸在肿瘤生长中发挥重要作用,精氨酸代谢紊乱可能影响肿瘤的进展。双甲基精氨酸水解酶亚基1[N(G),N(G)-dimethylarginine dimethylamino hydrolase 1,DDAH1]可以通过DDAH1/不对称二甲基精氨酸(asymmetric dimethylarginine,ADMA)/一氧化氮(nitric oxide,NO)通路参与调控精氨酸的代谢,进而影响肿瘤的进展。本文主要综述DDAH1代谢通路及其调节机制、DDAH1在肿瘤中的研究进展,以及针对DDAH1靶向分子抑制剂的临床转化研究,旨在系统地展示DDAH1在肿瘤诊断、监测和治疗中的分子病理机制研究进展与临床转化领域的应用前景。Metabolic reprogramming represents a characteristic feature of malignancy,which can be exploited for the diagnosis,monitoring,and treatment of cancer.Dysregulation of the L-arginine metabolic pathway has been consistently detected in tumors,and DDAHI is involved in the metabolism of arginine through the DDAH1/ADMA/NO pathway,by affecting tumor progression.This review primarily elucidates the DDAH1 metabolic pathway,the regulation of DDAH1,and the research progress in DDAHI with respect to tumors.Additionally,the latest progress in the clinical translation of DDAH1-targeted molecular inhibitors is discussed,which provides novel insights for cancer treatment.

关 键 词：DDAH1 精氨酸代谢 肿瘤 

分 类 号：R730.2[医药卫生—肿瘤]